曲妥珠单抗为基础的新辅助化疗治疗 HER2 阳性乳腺癌患者中 HER1、HER3 和 HER4 的免疫组化表达。
Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
机构信息
Breast and Medical Oncology Division, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
出版信息
J Surg Oncol. 2010 Mar 1;101(3):222-7. doi: 10.1002/jso.21486.
BACKGROUND AND OBJECTIVES
The aim of the present study was to examine the association between the expression of human epidermal receptor (HER) 1, HER3, and HER4 and pathologic complete response (pCR) in HER2-positive patients treated with trastuzumab-containing neo-adjuvant chemotherapy.
METHODS
Immunohistochemical analyses of HER1, HER3, and HER4 were performed using tumor specimens obtained from patients treated with trastuzumab-containing neoadjuvant chemotherapy. The staining intensity of each biomarker was evaluated, and the correlations between the immunohistochemical profiles and pCR were examined.
RESULTS
The present study included 44 patients with HER2-positive breast cancer treated with trastuzumab-containing neo-adjuvant chemotherapy. Seventeen patients achieved a pCR. The expressions of HER1, HER3, and HER4 were observed in 18.2%, 27.3%, and 18.2% of the specimens, respectively. A marginally significant negative correlation between the expression of HER1 and pCR was observed, irrespective of the expression of HER3 and HER4, whereas the expressions of HER3 and HER4 were not significantly correlated with pCR.
CONCLUSION
The expression of HER1 might be an independently negative predictor of pCR in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
背景与目的
本研究旨在探讨曲妥珠单抗为基础的新辅助化疗治疗 HER2 阳性患者中，人表皮受体（HER）1、HER3 和 HER4 的表达与病理完全缓解（pCR）之间的关系。
方法
采用免疫组织化学方法分析接受曲妥珠单抗新辅助化疗的患者的肿瘤标本中 HER1、HER3 和 HER4 的表达。评估每个生物标志物的染色强度，并检查免疫组化图谱与 pCR 之间的相关性。
结果
本研究纳入了 44 例接受曲妥珠单抗为基础的新辅助化疗的 HER2 阳性乳腺癌患者。17 例患者达到 pCR。HER1、HER3 和 HER4 的表达分别在 18.2%、27.3%和 18.2%的标本中观察到。无论 HER3 和 HER4 的表达如何，HER1 的表达与 pCR 呈负相关，尽管相关性不显著，但 HER3 和 HER4 的表达与 pCR 无显著相关性。
结论
在接受曲妥珠单抗为基础的新辅助化疗的 HER2 阳性乳腺癌患者中，HER1 的表达可能是 pCR 的独立负预测因子。
Zotero 插件